Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Cantargia, Audiocast, Q2'26

By Inderes8/19/2026, 1:00 PM
Cantargia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Hilde Steineger
00:02 - 22:17

Good afternoon and welcome to Cantargia's presentation of the second quarter and first-half year report for 2026. My name is Hilde Steineger, Chief Executive Officer at Cantargia, and I'm joined today by our Chief Financial Officer, Patrik Renblad. Today, I will take you through the operational and strategic progress during the quarter, including our clinical development plans and pipeline priorities. Patrik will then present the financial results for the second quarter and the first six months of 2026 before I return with a brief summary. Then, we will open the floor for questions. The central theme of today is how Cantargia continues to build on its leadership in IL1RAP antibody development, with nadunolimab as our lead oncology asset and with new opportunities emerging both in pancreatic cancer and hematologic malignancies. Next slide. Before we begin, I would like to remind everybody that today's presentation contains forward-looking statements. Forward-looking statements. These statements are subject to risks and uncertainties, and actual results may differ from those expressed or implied. We therefore encourage you to read through the Safe Harbor statement and the risk factors described in Cantargia's public disclosures. Next slide, please. Today's presentation will be structured in three parts. As mentioned, I will first summarize the key events and then review our pipeline. Next slide. The second quarter was a pivotal one for Cantargia, with meaningful progress on both the financial and clinical development fronts. First, we strengthened our balance sheet. A rights issue combined with a loan facility from venture capital delivered gross proceeds of 133. 32 million Swedish kronor. This capital is earmarked for our key strategic clinical priorities for nadunolimab, most notably the planned combination study with a KRAS inhibitor, daraxonrasib, in pancreatic ductal adenocarcinoma, or PDAC. Second, we extended nadunolimab's clinical footprint with a new investigator-initiated study at Mount Sinai. In this immunoprevention trial, the first patient, a high-risk smoker, has now been dosed with nadunolimab. Third, we published new scientific data reinforcing nadunolimab's mechanistic rationale in PDAC. These findings, published by JCI Insight in collaboration with the Sylvester Comprehensive Cancer Center at the University of Miami. Further, these findings validate IL1RAP as both a therapeutic target and a potential predictive biomarker. Strengthening our scientific and competitive positioning in PDAC. Finally, and perhaps most notably, we saw early but highly encouraging results from our ongoing investigator-initiated phase 1b/2a trial in high-risk myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. All five evaluable patients in the high-risk MDS cohort achieved complete remission, and at the reported data cut, with the sixth patient still pending, this is a signal that we view as clinically meaningful and a potential new value driver for nadunolimab. Taken together, these developments show Cantargia executing on multiple fronts at once, strengthening our financial position, advancing nadunolimab through key clinical milestones, and expanding the scientific case of IL1RAP as a validated target across both solid tumors and hematologic malignancies. This slide provides an overview of our IL1RAP-focused pipeline, and I've highlighted the initiatives that are currently the most active. Nadunolimab remains our lead oncology asset in PDAC. We are advancing our planned combination study with the KRAS inhibitor daraxonrasib, positioning nadunolimab within a rapidly evolving PDAC treatment landscape. As new agents and combination approaches reshape the standard of care in hematologic malignancies, specifically MDS and AML. The program is being run as an investigator-initiated study at MD Anderson Cancer Center, funded by the U.S. Department of Defense. This we see as a third-party validation of the underlying science that comes at no additional cost for us beyond nadunolimab. We're building our broader IL1RAP platform that includes CANxx, our proprietary engine for developing unique IL1RAP antibodies, as well as IL1RAP know-how and our CAN14 bispecific antibody program in autoimmune diseases, which is the program that has advanced the most. We have still CAN10. As an important part of our autoimmune franchise, CAN10, as you all know, is partnered with Otsuka, which is funding its continued development following the 2025 acquisition. The key takeaway of this slide is that Cantargia is not a single-asset company. We're building a focused but broad IL1RAP antibody platform with multiple shots on goal across both oncology and autoimmune diseases. And importantly, several of these programs are funded or partnered by third parties, which extends our capital efficiency. Let us now move into the oncology part of the presentation. In oncology, our focus is on the diseases where IL1RAP biology may be particularly relevant and where there is a significant unmet medical need. The two main areas I will discuss today are PDAC, MDS, and AML. Next slide. We will start with PDAC. One of the most aggressive and difficult-to-treat forms of cancer. PDAC remains a disease with very high unmet medical need, and Cantargia's strategy is to position nadunolimab in combinations where IL1RAP blockade may complement other emerging treatment approaches. We are responding proactively to the recent second-line PDAC data for daraxonrasib in the Phase 3 RESOLUTE-302 trial. Daraxonrasib showed a meaningful improvement in overall survival versus chemotherapy, a result that is important for patients. And the patients have very few options at this stage of the disease. This reinforces our rationale for combining nadunolimab with a KRAS inhibitor. And here we outline our planned Phase 1b study evaluating the combination in second-line PDAC. The study is designed as an open-label phase one trial evaluating the safety and tolerability of nadunolimab combined with daraxonrasib in patients with metastatic PDAC who have previously progressed on first-line standard of care. The planned study population is approximately 15 patients. The proposed regimen pairs nadunolimab at 5 mg/kg every two weeks with daraxonrasib at 300 mg once daily. The primary objective is to determine safety and tolerability. Secondary objectives will include preliminary signs of clinical efficacy, with exploratory objectives covering inflammatory, immune, and tumor microenvironment-related parameters in both circulation and tumor tissue. The study is expected to be initiated in the first quarter of 2026, subject to regulatory approval and daraxonrasib availability. The rationale for combining nadunolimab with daraxonrasib rests on the interaction between IL1RAP-driven inflammatory signaling and KRAS-driven tumor biology. KRAS fuels IL-1-dependent tumor inflammation, and IL-1 signaling through IL1RAP contributes to the self-sustaining inflammatory circuit in the tumor microenvironment involving both myeloid cells and cancer-associated fibroblasts. Importantly, nadunolimab acts through a pathway that runs parallel to rather than overlapping with the KRAS pathway, offering a complementary mechanism of action alongside RAS inhibition. Together, this builds a strong biologic rationale to explore whether IL1RAP blockade with nadunolimab can add further benefit in combination with a KRAS inhibitor. The scientific rationale is further supported by survival data showing that high IL1RAP RNA expression in PDAC tumors correlates with poor survival. Importantly, this relationship holds not only across all comers, but specifically also in patients with KRAS mutations, indicating that IL1RAP's prognostic value is not diminished by RAS status. For us, this is a meaningful data point. It reinforces IL1RAP not only as a therapeutic target, but as a marker of aggressive tumor biology in PDAC, including the KRAS-mutated patient, which is the most relevant patient population to our planned combination with daraxonrasib. Nadunolimab and Daraxonrasib have complementary mechanisms of action, each addressing a different compartment of the tumor. Nadunolimab targets IL1RAP, acting on both the immune compartment by dampening IL-1 driven inflammatory signaling along myeloid and T cells, and the stromal compartment, where it may help address the dense, drug-limiting stroma characteristic of PDAC. Daraxonrasib, by contrast, targets Ras signaling directly within the tumor cells, where KRAS mutation is a key driver of disease progression. By combining these approaches alongside standard chemotherapy, the aim is to address multiple interacting components of PDAC biology rather than a single pathway in isolation. It is, therefore, not simply an empirical combination. It is based on a mechanistic hypothesis that blocking IL1RAP-driven inflammation and stromal effects may complement Ras pathway inhibition and potentially improve the outcomes for a patient population with very limited treatment options. I will now move from solid tumors to hematologic malignancies, specifically MDS and AML. This is an increasingly important area for Cantargia because IL1RAP biology is highly relevant in leukemic stem cells, and because the medical need in high-risk MDS and AML remains substantial. The ongoing investigator-initiated phase 1b/2 study is evaluating Nadunolimab in this specific patient population. A study at M.D. MD Anderson Cancer Center is evaluating nadunolimab in exactly this patient population. The principal investigator is Gautam Borthakur, and the study is supported by a grant of the U.S. Department of Defense. The study started in 2025. It includes two arms. The study includes two arms. Arm one enrolls patients with intermediate, high, or very high-risk MDS, and arm two enrolls patients with relapsed or refractory AML in first or second salvage. The phase one part has been completed, and the study is progressing into phase two. Nadunolimab with azacitidine or with azacitidine and venetoclax was generally well tolerated across both patient groups with an acceptable safety profile, most notably in the high-risk MDS cohort. Five out of five evaluable patients achieved complete remissions, with the sixth patient pending at the January 2026 data cut. These are early data, and the numbers of patients are still small, but the results are highly encouraging and support continued evaluation of nadunolimab in high-risk MDS. The clinical observation in this study, as shown here, is also reinforcing IL1RAP as a high-risk marker. IL1RAP is overexpressed in leukemic diseases and is linked to adverse inflammatory and signaling profiles in AML. Higher IL1RAP expression has been associated with poor outcomes, as we saw in our PDAC clinical studies. This provides rationale for targeting IL1RAP in patients with particular high unmet need, including high-risk MDS and AML. Now, IL1RAP sits at the center of the disease biology in both MDS and AML. At the level of the leukemic stem cell itself, MDS originates from IL1RAP-positive leukemic stem cells in the bone marrow, which produce immature, non-functional blood cells. In MDS, blasts remain below 20% of the bone marrow cells, and MDS is classified into low, intermediate, and high-risk categories. High-risk MDS is likely to transform into AML within two years. AML, in turn, is defined by blast cells exceeding 20% of the bone marrow, also arising from IL1RAP-positive leukemic stem cells. It remains a highly lethal blood cancer, with survival rates of only 10% to 30% after five years. Current treatment relies on chemotherapy and stem cell transplantation. Transplantation, with only a limited number of targeted therapies available for specific genetic subtypes. Importantly, high I. Higher IL1RAP expression is also independently associated with poor survival in AML, reinforcing its relevance not just as a disease driver but also as a clinically meaningful biomarker, much like the one we discussed for PDAC. In short, IL1RAP is closely related to the biology of both diseases at the stem cell level, which is exactly what makes it an attractive therapeutic target. A central challenge in MDS and AML is that leukemic stem cells can escape current chemotherapy strategies, thereby creating a reservoir for relapse. There is therefore a very strong medical need for therapies that target leukemic stem cells with specificity. IL1RAP fits that need. It is expressed on leukemic stem cells in AML and high-risk MDS, but not on normal hematopoietic stem cells. Nadunolimab targets IL1RAP in these leukemic stem cells, aiming to block proliferation and label cells for killing through antibody-dependent cellular cytotoxicity, or ADCC. This is core to the therapeutic concept, targeting disease-driven cells through a mechanism that is biologically differentiated from standard cytotoxic treatment. High-risk MDS represents a meaningful clinical and commercial opportunity for Cantargia. Globally, there are approximately 400,000 MDS patients, with high-risk patients representing around 35% of that population. Median survival in high-risk MDS is just 1 to 2 years. Current backbone treatment relies on hypomethylating agents or HMA's such as Vidaza, Dacogen, and Inqovi. Yet a significant unmet need remains. Stem cell transplantation is the only intervention with curative potential, but 70% of patients are not eligible for this. In addition, about half of the patients do not respond to HMA therapy, and effective post-relapse treatment options are lacking. Median overall survival in this setting with HMA-resistant disease is only 5 to 6 months. Resistance is only 5 to 6 months. The global high-risk MDS population is approximately 150,000 patients, and this market is estimated to be approximately $4.5 billion in 2028 and projected to grow to around $11.2 billion in 2034. For Cantargia, the strategic case is clear: high-risk MDS combines a strong biologic rationale in IL1RAP, targeting a high unmet need and a potentially significant market opportunity. Beyond nadunolimab. We are also advancing our next-generation IL1RAP therapeutics; CANxx is our program for new therapeutics and reagents built on our deep knowledge of IL1RAP and its role in disease biology. That knowledge base includes a library of approximately 200 high-affinity antibodies. Now reaching up to 500 anti-IL1RAP antibodies and clones developed within the platform. These antibodies bind to different domains of IL1RAP and carry different functional properties, giving us a broad toolkit to pursue multiple therapeutic strategies rather than a single mechanism of action. CAN10 was the first program to originate from this platform, and CAN14 is the second, adding new features to IL1RAP blockade. CAN14 is the second, adding new features to IL1RAP blockade. Together, they illustrate the broader value of our IL1RAP platform. And we are not developing a single antibody. We are building a pipeline of differentiated, IL1RAP-directed therapeutic strategies. Our next-generation strategy builds on the observation that IL1RAP blockade is a potent way to block inflammation in preclinical and translational ex vivo models. We are exploring bispecific antibodies, which can add new functionalities to IL1RAP blockade and be tailored to specific diseases. We're also exploring antibody-drug conjugates, or ADCs, which combine cytotoxicity and IL1RAP targeting in one single molecule to increase efficacy and concentrate the effect. The broader rationale holds across both approaches. IL1RAP is expressed in a large number of solid and hematologic tumors with limited expression in normal tissue. This concludes our operational and pipeline section. I will now hand over to Patrik Renblad, who will take us through the financial results of the quarter and the first six months. Patrik, over to you.

Patrik Renblad
22:18 - 29:00

Thank you, Hilde. I will now take you through the financial results for the second quarter and the first six months, focusing on our profit and loss, operating expenses, and cash flow and cash position. For the second quarter of 2026, our revenues amounted to 100,000 Swedish kronor. Operating expenses were 35.9 million kronor, resulting in an operating loss of 35.8 million kronor. That was offset by positive net financial items amounting to 3 million, totaling a loss for the period of 32.8 million kronor. And our reported loss per share was 0.13 kronor. Looking now at the first six months of the year, our revenues amounted to 0.6 million Swedish kronor, all derived from the Otsuka collaboration. Our operating expenses were 73.3 million SEK, leading to an operating result of 72.7 million SEK. Again, here we had that offset by positive net financial items amounting to 6.9 million for the first half of the year and a loss for the period of 65.8 million, corresponding to a loss per share of 0.26 kronor. Diving a little bit deeper into our operating expenses, we reported a decrease compared with the corresponding period last year, both on a quarter and on a year-to-date basis. In the quarter, our operating expenses fell 9% from 39.5 million kronor in 2025 to 35.9 million kronor. And for the six months, our operating expenses were 73.3 million, compared with 84.5 million in the first six months of 2025, corresponding to a decrease. Year to date of 13%. As expected for a clinical-stage biotech company, the operating expenses are primarily driven by research and development activities. Operating expenses are primarily driven by research and development activities. Together with the administrative expenses required to support our operations. Our development programs. Now, the decrease reflects relatively low R&D activity driven both by the Cantargia divestment and operational timing. Here, as a reminder, Cantargia was still in our books in the comparison period, and we had both an ongoing clinical study as well as preparations for the next stage of the development of that asset. In the results for the second quarter and the first half of 2026. It is also worth mentioning that nadunolimab activities are lower than what we had in the previous year as preparations for the next clinical study. The combination study with daraxonrasib has only started now after the completion of the financing this summer. Now, a few words on general and administration that admittedly has increased. The first reason is that we are comparing it with a period last year where our main focus was the negotiation with Otsuka. So all other activities were basically put on hold at an unsustainably low level. During the first six months of this year, we have incurred external costs, for example, related to contract negotiations supporting our programs, but classified as general and administration, making sure that we prioritize the activities that are most important for the development of nadunolimab and our IL1RAP platform. Turning to cash flow and cash position. Our operating cash flow in the second quarter was -37 million SEK, compared to -44 million in the second quarter of 2025. Perhaps more importantly, our available funds exclude the proceeds from the rights issue and the loan that were booked and recognized after the end of the reporting period. Going back, our available funds amounted to 222 million SEK as of June 30th, 2026, compared with 82 million SEK at the same time point in 2025. The current available funds, plus the proceeds from the rights issue and the loan, are expected to fund several key prioritized activities. I've listed them here, but I will also read them for completeness. So the planned phase 1 study of nadunolimab in combination with daraxonrasib in second-line metastatic PDAC is funded. The expansion of the phase 1b/2 investigator-initiated trial at MD Anderson Cancer Center in hematological malignancies is also funded. We have ongoing commitments related to nadunolimab. For example, the TRIFORCE study, which has stopped recruiting but is not yet completed, is one such ongoing commitment. We have decided to invest in the next generation of anti-IL1RAP antibodies, including CAN14 and CANxx, as Hilde just mentioned. And those are also funded by the rights issue. And we will keep the company funded to mid-2028. I would also like to mention that this cash runway estimate excludes any potential milestones payable to us or Cantargia from Otsuka. And that principle will remain until that development program has reached a more mature, late stage. With that, I will conclude my part and hand over to Hilde for closing remarks. Hilde, over to you.

Hilde Steineger
29:03 - 29:29

Thank you, Patrik. To summarize, the financial position supports our ability to execute on the most important value-driving activities in the portfolio, advancing nadunolimab in PDAC, continuing development in hematologic malignancy, and investing selectively in the next generation of high-affinity IL1RAP therapeutics. With that, I will open up for questions.

Operator
29:31 - 29:35

The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
29:37 - 30:02

Good afternoon. I have a few questions on the program, starting with the financial part. You raised around 130 million SEK gross from the rights issue plus loan. How much of that goes to this one study with 15 patients? It sounds like that should be more than enough.

Hilde Steineger
30:06 - 30:33

I can start and Patrik, maybe you can chime in. We will start with the 1b study first and then we will advance into a 2a setting. So, for now, our first milestone will be a 1b. So, the bulk of the rights issue is targeted towards this study.

Richard Romanus
30:40 - 30:52

Okay. And I also wanted to ask about the status of the IL1RAP diagnostic assay. Is it approaching readiness?

Hilde Steineger
30:53 - 31:23

Well, right now we are not investing in a full-blown, phase three ready, diagnostic kit. We will not proactively select patients in our 1b/2a study. We will measure IL1RAP retrospectively. So, we have put that on a low burner until we get further into the development path.

Richard Romanus
31:26 - 31:54

Okay, then. A last question. Revolution Medicines obviously produces daraxonrasib, which you will use in your study. Have you had any discussions with them about this? It would be nice, for example, to have a substance agreement.

Hilde Steineger
31:56 - 32:36

So of course, we discuss with a lot of different partners on different levels. However, we are not dependent on drug supply from daraxonrasib in our study. We expect daraxonrasib to be approved quite soon in the near future and it will therefore be a part of standard of care that the patients will receive at the different sites and clinics that will be part of our study. Yes, having an agreement with Revolution Medicines would be beneficial, but we are not dependent on that.

Richard Romanus
32:39 - 32:41

All right. Thanks for asking my questions.

Hilde Steineger
32:43 - 32:44

Thank you. Thank you, Richard.

Operator
32:46 - 33:13

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Unknown 1
33:14 - 33:52

We will continue with some of the questions coming in through the web. And the first one is regarding hematology timing. In the report, it is guided that the completion of the phase two study is expected. A portion of the trial. It is to. Mid-2027 is an interim disclosure at venues such as ASH 2026, as contemplated in the interim. Also, it is an investigator-initiated trial. But could you give any color on the enrollment pace towards the 40-patient target? That would be helpful. Thanks.

Hilde Steineger
33:53 - 34:36

Um thank you. As mentioned, it is a study run by MD Anderson, and we are not in control of recruitment timelines and enrollment. However, we have been informed by MD Anderson that they have submitted an abstract to ASH. We have then also reviewed the embargo timelines, which is November 4th. So we expect that the ASH abstract, if approved by ASH, will be available on November 4th.

Unknown 1
34:38 - 34:58

Thank you. And the second question is regarding the R&D trajectory. Regarding the trajectory. R&D is down 22% year on year. But could you give a flavor on the ramp up on this one during the second half of this year and into 2027.

Hilde Steineger
34:59 - 35:01

Patrik, do you want to take that?

Patrik Renblad
35:01 - 35:57

Yes, I will see if I can provide some context regarding that question. Thank you. Jonas. We are, as I mentioned, in a period now where we are ramping up preparations for the combination study with daraxonrasib. So that will ramp up gradually here during the remainder of this quarter and the fourth quarter. Before we can really see the study kicking off, we hope it will be as early as possible next year. So yes, that will be in effect; our investment in the early platform is also expected to continue and potentially increase slightly during the remainder of the year. Thank you. I hope that provided some insight. If not, I am open to more questions about that.

Unknown 1
35:58 - 36:17

Yes. Hilde, you were earlier talking about the selection of high IL1RAP patients for the phase 1b study. But just to reiterate, you will not select patients beforehand in that part of the study, correct?

Hilde Steineger
36:17 - 36:31

That is correct. We will measure retrospectively, and the 1b/2a study will be all-comers. So we will treat all comers in this study.

Unknown 1
36:32 - 36:55

Thank you. And in terms of how you are prioritizing the different programs, can you give some thoughts on where you believe the most value lies now? Is it nadunolimab with the daraxonrasib combination in PDAC, or development in high-risk MDS, or the preclinical bispecific antibody programs?

Hilde Steineger
36:56 - 37:51

Well, to start with, the preclinical pipeline consists of early initiatives and will provide a stream of pipeline opportunities as we go along. However, it will take some time until they are ready to enter into phase one. I would say that choosing between PDAC and MDS would be almost like choosing your favorite child. We think that both of them are extremely interesting, both commercially and medical-need wise. So, I think that the favoritism is close; it is easier to answer that question when we know more about the clinical results. I would weight them equally.

Unknown 1
37:52 - 38:15

Thanks. It seems like we are coming to the end of these questions from the web, specifically regarding the supply of daraxonrasib. And just to reiterate, you don't think that this will be a constraint on enrollment of patients in the first quarter of 2027?

Hilde Steineger
38:16 - 38:49

No. The clinicians and centers that we've been talking to with regards to this study are all very optimistic that daraxonrasib will be approved in the near future. And that will then be a standard of care also adopted immediately. These clinics will then start using daraxonrasib in second line immediately. And we can then build on that in the clinics that we've chosen.

Unknown 1
38:51 - 38:58

Thanks. That concludes all the questions received from the web. So I'll hand over to you, Hilde, for any concluding remarks.

Hilde Steineger
38:59 - 39:13

Well, thank you all for joining today. We appreciate your continued engagement and support, and we'll keep you informed as we execute our programs. Thank you all and have a great day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…